Summary While radiotherapy is proceeding. tumour cells may proliferate. The use of small individual doses reduces late morbidity. Continuous hy-perfractionated accelerated radiation therapy (CHART). which reduces overall treatment from 6-7 weeks to 12 days and gives 36 small fractions. has now been tested in multicentre randomised controlled clinical trials. The trial in non-small-cell lung cancer included 563 patients and showed improvement in survival: 30% of the CHART patients were alive at 2 years compared with 20% in the control group (P=0.006). In the 918 head and neck cases. there was only a small. non-significant improvement in the disease-free interval. In this interim anlavsis there was a trend for those with more advanced disease (T3 and T4) to show advantage: this will be subject to further analysis when the data are more mature. The earlv mucosal reactions appeared sooner and were more troublesome with CHART. however they quickly settled: so far no difference in long-term morbidity has emerged. These results support the hypothesis that tumour cell repopulation can occur during a conventional course of radiotherapy and be a cause of treatment failure.
Radiotherapy plays an important role either alone or in combination with surgery and cytotoxic chemotherapy in the management of many primary malignant tumours. When employed as the single modality to achieve local cure. the commonest schedule currently employed worldwide requires daily treatment from Monday to Friday over a period of 6 to 7 weeks. Using an individual dose of 2 Gy. total tumour doses between 60 Gy and 70 Gy are achieved. Developments in radio and tumour biology have now led to a reexamination of this established conventional scheduling of radiotherapy.
Giving radiotherapy in many small doses has been shown to reduce the long-term effects in a number of normal tissues with little reduction in effect upon most tumours (Withers. 1992; Fowler. 1989) . Treating in this way. higher total doses are tolerated by the normal tissues and greater tumour control can be achieved (Horiot et al., 1992) .
Increased knowledge of the cell kinetics of human tumours has been gained by the administration of bromodeoxyuridine followed by a tumour biopsy after 4 to 8 h and analysis using flow cytometry (Begg et al.. 1985) . When untreated cancers are observed, they usually take between 25 and 100 days to double their volume (Charbit et al.. 1971) . In contrast. cell kinetic studies now show mean potential cell doubling times ranging from 4 to 7 days for tumours in the head and neck.
lung, uterine cervxVX and digestive tract (Dische and Saunders. 1995 ). An extension of the technique has allowed identification of the cells preparing for division in histological material and has shown that in most squamous cancers there are areas where there is a potential for the number to double in less than 2 days (Bennett et al., 1992) . High cell loss factors owing to maturation and degeneration largely account for the difference between the volume doubling times and potential cell doubling times of these tumours (Denekamp, 1982) . When. after cytotoxic chemotherapy or radiotherapy, large numbers of tumour cells are destroyed. these cell loss factors may greatlN diminish and a repopulation of the tumour occur during the intervals between individual treatments (Tubiana. 1988) .
In order to minimise repopulation. attempts have been made to reduce the overall duration of the course of radiotherapy. However. when treatment is 'accelerated' reactions in the normal tissues are more severe. especially if the normal dose increment of 2 Gy is employed. thus making it difficult to achieve adequate total doses (Peracchi and Salti. 1981; Olmi et al.. 1990 ). Most approaches have incorporated individual doses lower than 2 Gy and have attempted to reduce overall time by only 1 or 2 weeks (Dische and Saunders, 1995) .
Among the recently introduced regimens. continuous hyperfractionated accelerated radiation therapy (CHART). first used at Mount Vernon in Januar-1985 . was unique in that it reduced the overall duration of treatment to the shortest period attempted -12 days (Sanders et al.. 1991) . A small dose of 1.5 Gy was given three times per day on every day. including Saturday and Sunday. Immediate tolerance to the regimen was better than anticipated and there was evidence that the long-term effects in normal tissues were reduced. When, in head and neck cancer. a historical comparison was made with previously treated patients. improved local tumour control was observed. In locally advanced non-small-cell lung cancer (NSCLC) there was, in a similar analysis. improved local tumour control and survival The planning of radiotherapy
The planning process was identical for all patients regardless of randomisation. Radiation doses were prescribed to the intersection point as defined by international recommendations (ICRU, 1978) . During the main part of the course of treatment, the volume irradiated included the primary tumour, Survival and disease-free interval curves were formed by the Kaplan-Meier method and compared using the MantelCox version of the log-rank test. To assess whether CHART was more or less effective in well-defined subgroups, a X2 test for heterogeneity or, when appropriate, trend was performed. All analyses were performed on an intention-to-treat basis, all tests are from the x2 distribution with one degree of freedom and all P-values were two-sided unless otherwise specified.
The statistical methods used were implemented using BMDP and SAS (Parmar and Machin, 1995 cancer and 563 with NSCLC were entered by 13 centres ( able I). The peak of entry to the head and neck study was in the secndr venr of the trinl hut subhseoueuntlv an averaye of 12 canse were included each month. Entry to the lung study was at a lower level but maintained at around ten cases per month during the whole period of accrual. A review of the patient characteristics (Table II) There was a high degree of conformity to protocol, including the delivery of the planned radiotherapy. The size of the treatment fields and the homogeneity of radiation dose through the volumes irradiated were similar in both arms of both trials. Deviations from the protocol were slightly greater in the conventional arms but the differences L LJ between the treatment groups were small and to be expected (Figure 2b-d) .
In the lung trial, complete tumour regression was observed in 34% of CHART patients and 29% of the conventionally treated patients. There was a trend for the improved tumour control to be maintained with CHART but this did not reach statistical significance (P=0.15, x2= 2.04). 
Among the head and neck patients, 362 deaths have occurred so far, whereas 379 of those with lung carcinoma have died (Table III) . Death due to the primary tumour was the main cause of death in both trials but 32% of the deaths in the head and neck trial were due to coincidental disease and 5% to complications of other treatment given subsequently. In the lung study, only 13% of deaths were accounted to coincidental disease and 1% due to complications of other treatment.
In the head and neck study, the overall survival showed no difference between the two groups, but in the NSCLC trial there was improved survival for the CHART-treated patients (Figure 3a) with a hazard ratio of 0.75 (confidence interval 0.61-0.93, P=0.006, X2= 7.63). At 2 years, 30% of the CHART-treated patients were alive and 20% of those treated conventionally. There was a trend towards CHART being more effective with more advanced tumour stage but this did not reach statistical significance (P= 0.29, X2 = 1.13) (Figure  3b-d) .
Disui
When the CHART regimen was introduced, it was suggested that early reactions in both the skin and the mucosa would be more severe than with conventional treatment. Previously reported clinical trials of accelerated radiotherapy which were completed in 2 weeks using a conventional 2 Gy dose fraction in head and neck cancer resulted in mucosal reactions of great severity which in some cases did not heal and led on to necrosis (Peracchia and Salti, 1981; Olmi et al., 1990) . The use of a small dose per fraction (1.5 Gy) appeared to ameliorate the acute mucosal reactions which, although they appeared earlier and were more troublesome than with conventional treatment, settled sooner, with no more cases of persistence than with conventional treatment.
Of special interest was the diminished reaction in skin. Completion of all radiotherapy before significant reaction was visible in the skin may have increased tolerance because when compensatory proliferation in the normal skin occurred it could proceed without inhibition by further irradiation. A similar finding has now been reported in the skin of pigs (Hopewell and Van Den Aardweg, 1991) . The use of CHART in those patients where the full thickness of skin must be irradiated has given a well-tolerated reaction unlike that normally observed with conventional radiotherapy (Dische, 1992) .
Transient myelitis after radiotherapy is not associated with any long-term problem (Jones, 1964) . It appeared to be associated with CHART in the lung trial but the distribution in the head and neck trial was exactly according to randomisation. In both trials, the late changes owing to radiation so far observed have been similar in both arms. Further follow-up will show whether the diminished late change associated with CHART and demonstrated in the pilot study will be observed in the randomised trials .
For this interim report the disease-free survival of the head and neck patients is reported. As distant metastasis was usually associated with failure in the primary tumour and/or nodes, this closely parallels disease-free probability within the irradiated volume. The definitive report to be produced when the data mature will fully detail the outcome in these patients.
In the conventionally treated arms of the trials, the predicted tumour-free survival of 45% for the head and 
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4 neck cases was exactly reproduced in the randomised trial while in patients with lung carcinoma there was 20% survival at 2 years compared with a predicted 15%. Disease-free interval was considered the most sensitive indicator of the treatment effect in the head and neck cases; it was almost identical to recurrence rate within the treatment volume; distant metastasis without local failure was rare. In NSCLC, the measurement of local response and detection of recurrence is more difficult to achieve and thus survival was considered to be the principal end point. Where there has been intensive study of primary tumour control in NSCLC, the complete clearance of tumour has been a strong predictor of survival (Saunders, 1991) .
Patients presenting with head and neck cancer and those with lung cancer commonly have a history of heavy cigarette smoking and often of high alcohol consumption. Their survival is therefore prejudiced not only by the presence of the tumour for which they are being treated but by the other conditions associated with their lifestyle. The difference between the trials in the incidence of death due to coincidental disease can, in part, be related to the longer survival of the head and neck patients. The greater possibility of a salvage procedure for recurrence of metastases -surgery and cytotoxic chemotherapy -accounts for the 5% incidence of death due to complications of other treatment of which there were only 1% in the patients with lung cancer. Deaths considered due to radiotherapy were rare in both studies.
The trend for improved local tumour control by CHART compared with conventional treatment with increasing stage of disease occurred also in the pilot study of CHART in head and neck cancer . The data on which this interim report is based were obtained on the same day as case accrual ceased. With further follow-up considerably more data will be available for subgroup analysis and to test the view that patients with advanced stage disease obtained greater benefit with CHART than those with tumours at earlier stages.
Tumour control in the earlier stages of head and neck cancer appeared in both arms of the trial. The choice of CHART for such patients may still be appropriate if a reduction in late morbidity is demonstrated and if the observation that surgery after CHART is easier than after conventional radiotherapy is confirmed in further follow-up. It was apparent that, although patients were prepared to be randomised, a large majority found the completion of all treatments in a 12 day period preferable to daily attendance over a period of 6 to 7 weeks even though a stay in a hostel or ward might be required for the three times a day treatment. (M Leslie, S Dische and MI Saunders, in preparation) . The patients' choice may therefore influence the selection of treatment schedule towards CHART.
Sophistication in the delivery of radiotherapy now available using conformal techniques may allow higher doses to be achieved using CHART at the site of gross tumour without increase in morbidity. Further, it may be possible to combine the accelerated treatment with cytotoxic chemotherapy. Using these approaches, additional margins of benefit may be achieved. The CHART regimen may also be applied with advantage to tumours at other sites.
To achieve completion of CHART in 12 days, the total dose was reduced to 54 Gy. It was originally anticipated that the benefit of overcoming tumour cell repopulation would more than compensate for a reduction in the total radiation dose of 12 Gy to the head and neck tumours and 6 Gy to the lung carcinomas. The results of the randomised controlled clinical trials confirm this view and show that the disadvantage of a small reduction in total dose can be outweighed by the benefit of reduced overall time. The differences in result seen between the two trials may be related to the 18% reduction in total dose required to give CHART to the head and neck cases and the 9% for those with lung cancer.
The potential for tumour cells to proliferate rapidly may occur at other sites and have a wide importance in oncology. After surgical resection of tumour, any residual cells may proliferate rapidly in the well-vascularised post-surgical bed. Between cycles of cytotoxic chemotherapy residual tumour cells may be expected to divide rapidly. The shortening of overall time associated with dose intensification in cytotoxic chemotherapy should, in itself, give advantage. The evidence gained in patients treated by radiotherapy showing the ability of tumour cells to proliferate rapidly suggests that when the plan of management is for a combination of treatment modalities -surgery, radiotherapy and cytotoxic chemotherapy -rest intervals between each should be kept as short as possible. Once cancer treatment commences, the greatest success may follow the completion of all its phases in the shortest overall period of time.
